TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 15.29

Change

0.00 (0.00)%

Market Cap

USD 38.25B

Volume

7.75M

Analyst Target

USD 12.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-3.89 (-2.38%)

USD 72.21B
TAK Takeda Pharmaceutical Co Ltd A..

+0.21 (+1.40%)

USD 47.88B
HLN Haleon plc

+0.29 (+2.85%)

USD 46.89B
RDY Dr. Reddy’s Laboratories Ltd..

+0.01 (+0.08%)

USD 10.62B
ELAN Elanco Animal Health

-1.05 (-9.75%)

USD 5.51B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.36 (-4.41%)

USD 4.11B
BHC Bausch Health Companies Inc

-0.44 (-7.20%)

USD 2.64B
CPHI China Pharma Holdings Inc

-0.01 (-4.56%)

USD 3.69M
YCBD cbdMD Inc

-0.04 (-14.39%)

USD 1.96M
EBS Emergent Biosolutions Inc

-0.34 (-6.58%)

N/A

ETFs Containing TEVA

FLWR:SW 5.80 % 0.00 %

N/A

N/A
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

-2.21 (0%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRPF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 2.22B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

-1.87 (0%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

-1.49 (0%)

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

-0.54 (0%)

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

-0.47 (0%)

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
ISRWF 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.63% 14% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.63% 14% F 4% F
Trailing 12 Months  
Capital Gain 8.29% 64% D 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.29% 64% D 65% D
Trailing 5 Years  
Capital Gain 82.02% 85% B 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.02% 77% C+ 49% F
Average Annual (5 Year Horizon)  
Capital Gain 13.26% 71% C- 73% C
Dividend Return 13.26% 71% C- 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.84% 43% F 22% F
Risk Adjusted Return 30.96% 71% C- 45% F
Market Capitalization 38.25B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector